Literature DB >> 11471788

Post-Daubert admissibility of scientific evidence on malingering of cognitive deficits.

B Vallabhajosula1, W G van Gorp.   

Abstract

In Daubert v. Merrell Dow Pharmaceuticals, Inc. (1993) the Supreme Court held that evidence must be "reliable" to be admissible and for scientific evidence "evidentiary reliability" is based on scientific validity. This article addresses the question "Do the Rey 15-Item Test ('FIT'), the Test of Memory Malingering ('TOMM'), and the Validity Indicator Profile ('VIP') likely meet the Daubert standard for admissibility of scientific evidence?" Sensitivity, specificity, positive and negative predictive values (PPV and NPV, respectively), and base rates of 30 and 15 percent were calculated for each test. Given the existing literature on malingering and the implications of a misclassification of malingering, we discuss the findings for each of the three tests using a PPV > or = 80 percent with a base rate of malingering of < or = 30. Our analyses indicate that the Rey 15-FIT fails to meet this standard of scientific validity. In contrast, the TOMM shows high specificity and PPV, and our findings suggest cautious optimism regarding the VIP. These results are discussed within the context of the courts' guidelines for the Daubert standard.

Entities:  

Mesh:

Year:  2001        PMID: 11471788

Source DB:  PubMed          Journal:  J Am Acad Psychiatry Law        ISSN: 1093-6793


  3 in total

1.  Prevalence and Assessment of Malingering in Homicide Defendants Using the Mini-Mental State Examination and the Rey 15-Item Memory Test.

Authors:  Wade C Myers; Ryan C W Hall; Marina Tolou-Shams
Journal:  Homicide Stud       Date:  2012-11-06

2.  Using the yes/no recognition response pattern to detect memory malingering.

Authors:  Sebastian Schindler; Johanna Kissler; Klaus-Peter Kühl; Rainer Hellweg; Thomas Bengner
Journal:  BMC Psychol       Date:  2013-06-25

Review 3.  Testing Claims of Crime-Related Amnesia.

Authors:  Marko Jelicic
Journal:  Front Psychiatry       Date:  2018-11-21       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.